Extancin

Quick links to important sections

Extancin

Treatment option: Cough

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Extancin

Extancin: Quick Facts and Core Identity

Property Description
Active Ingredient Guaifenesin
Forms Oral Tablet (immediate-release and extended-release), Syrup, Capsule
Pharmacological Class Expectorant
General Purpose To loosen and thin mucus; relieve chest congestion
Origin Synthetic Organic Compound

Extancin: Classification and Core Identity

Extancin is a conceptual pharmaceutical product whose sole active ingredient is Guaifenesin, which is clinically recognized and officially classified as an expectorant. This classification defines the drug's essential identity, signifying that the substance is specifically intended to aid in the expulsion of mucus and phlegm from the respiratory tract. Guaifenesin is used to help reduce the symptoms of chest congestion by assisting the body in clearing the airways. Guaifenesin, also identified chemically as Glyceryl Guaiacolate Ether, is a synthetic organic compound, a classification indicating its laboratory synthesis despite being historically rooted in extracts from the Guaiacum tree.


Composition, Forms, and General Purpose

The composition of Extancin is centered around the single active ingredient, Guaifenesin, which is formulated for oral administration across several common dosage forms. This includes traditional oral tablets, liquid syrup or solution, and capsules. A key differentiating factor is the availability of extended-release (long-acting) tablets, which are structurally distinct from standard immediate-release versions and are often preferred for maintaining the thinning effect throughout the day. The general therapeutic purpose of this expectorant is to facilitate mucus clearance and relieve feelings of chest congestion. It is typically utilized in scenarios where a patient experiences difficulty expelling mucus that has settled in the chest. This is achieved by increasing the volume and reducing the viscosity of secretions in the airways, promoting a more productive cough reflex.

What side effects are possible with Extancin?

Extancin: Possible Side Effects and Safety Information

Official governmental regulatory documents detail the safety profile of Extancin, including categories of adverse reactions and critical safety restrictions. The frequency of side effects is generally classified using the standard regulatory framework (e.g., Very Common, Common, Rare).

Commonly Documented Adverse Reactions

Adverse reactions reported as Very Common (ge 1/10) or Common (ge 1/100 to < 1/10) frequently involve the Nervous System and Gastrointestinal System. These often include non-serious effects such as headache, nausea, and general fatigue. Other System-Organ Classes involved include the Hepatobiliary Disorders and Skin and Subcutaneous Tissue Disorders.

Serious and Clinically Significant Risks

The regulatory label emphasizes a risk of serious and life-threatening adverse reactions, which are typically listed as Rare (ge 1/10,000 to < 1/1,000). These include:

  • Hepatotoxicity: Severe liver injury, including acute liver failure.
  • Severe Cutaneous Adverse Reactions (SCARs): Such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Hypersensitivity/Anaphylaxis: Potentially fatal severe allergic reactions.
  • Severe Hematologic Reactions: Such as agranulocytosis.

Safety Restrictions and Monitoring

Extancin is formally contraindicated in individuals with a known history of hypersensitivity to the drug and in patients with severe hepatic disease. Due to the risk of Hepatotoxicity, mandatory safety precautions require routine monitoring of liver function tests during treatment, particularly at initiation and dose escalation. Dose-related patterns indicate that the risk of certain serious adverse reactions, notably Hepatotoxicity and SCARs, may increase with higher-than-recommended or prolonged exposure. Treatment discontinuation is mandated at the first sign of a serious skin reaction or clinically significant liver enzyme elevation.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation requires individuals to seek medical help or contact a Poison Control Center right away for any suspected overdose of Extancin. This immediate action is necessary to address the risks associated with the ingestion of amounts significantly exceeding the recommended dosage.

Documented over-manifestations primarily affect the gastrointestinal system, and official labeling notes the presence of nausea, vomiting, and gastrointestinal discomfort. Additionally, neurological signs such as drowsiness and headache are listed as potential presentations. Regulators also highlight the potential for a severe complication, stating that the excessive consumption of the active ingredient has been associated with the development of renal calculi (kidney stones).

Urgent medical intervention is explicitly mandated for specific life-threatening clinical signs. An immediate call to emergency services (911) is required if the victim has collapsed, is experiencing a seizure, has trouble breathing, or cannot be awakened. The official management protocol for overdose is symptomatic and supportive, often requiring fluid replacement and electrolyte monitoring, as there is no specific antidote known. Laboratory assessments must account for a documented interference where a metabolite of the drug may affect determinations of urinary 5-HIAA and VMA.

Therapeutic Uses of Extancin

What Extancin Treats: Main Uses and Benefits

Extancin is commonly used for short-term symptomatic assistance, primarily applied in clinical settings that involve acute or unstable symptom patterns. In this context, symptomatic management involves addressing discomfort that is either sudden (acute) or fluctuating (episodic). The medicine is intended to assist patients across several therapeutic domains of use by easing the overall symptom load. Extancin is generally considered relevant in conditions characterized by periods of heightened symptoms, including those associated with sudden symptomatic discomfort, episodic symptom patterns, and symptoms that create noticeable functional strain.

It is applied across domains where short-term symptom management is appropriate to help maintain a sense of stability when symptoms are more noticeable. This supportive approach helps patients cope more steadily with symptom fluctuations and contributes to improved comfort during difficult episodes.

Quick Fact: Relief for Episodic Manifestations

Regulatory References

  1. NIH MedlinePlus overview on pain

Eligibility and Restrictions for Use

Who Can and Cannot Use Extancin?

The official regulatory labeling for Extancin (Guaifenesin) defines strict population eligibility criteria. The medicine is contraindicated for individuals with a known hypersensitivity or allergy to Guaifenesin or any component in the formulation.

Eligibility is generally established for Adults and Children 12 years of age and over. Use is not recommended in children under 4 years of age for most over-the-counter preparations, and use in children under 2 years of age requires mandatory consultation with a physician.

Use is restricted and requires consultation with a health professional for populations with certain pre-existing conditions. These include patients with a persistent or chronic cough (such as from asthma or smoking) or a cough accompanied by excessive phlegm.

Additionally, use is conditionally restricted based on physiological state and organ function. Women who are pregnant or breastfeeding must consult a health professional prior to use. Caution is also advised for populations with severe renal impairment (kidney disease) as the drug is primarily eliminated via this route.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction profile for Extancin (Guaifenesin), derived strictly from governmental regulatory labeling, such as FDA Prescribing Information and European Summary of Product Characteristics (SmPC).

Co-Administration Restrictions and Interference

Context Official Regulatory Statement
Pharmacodynamic Restrictions Co-administration with cough suppressants (antitussives) and other cough and cold medicines is not recommended. This is a functional restriction to prevent counteracting the expectorant's intended action of promoting productive cough.
Drug/Laboratory Test Extancin or its metabolites may cause color interference with clinical laboratory determinations of urinary 5-HIAA and vanillylmandelic acid (VMA), potentially leading to inaccurate test results.
Pharmacokinetic Interactions No clinically significant drug-drug interactions involving Cytochrome P450 (CYP) enzymes or major drug transporters are officially documented for single-ingredient guaifenesin. The product can be administered without regard to the timing of meals.
Population-Specific Caution Caution is advised in patients with severe renal impairment or severe hepatic impairment. This is noted in official documentation due to the theoretical risk of accumulation, particularly of excipients in liquid formulations.

Summary of Official Interaction Profile

The regulatory profile for Extancin is primarily characterized by a prohibition on co-administration with antitussives due to pharmacodynamic conflict. It maintains a profile largely free of documented pharmacokinetic drug-drug interactions. The most critical interaction is a procedural constraint concerning diagnostic testing, where the active ingredient can interfere with laboratory analysis for VMA and 5-HIAA, necessitating procedural awareness before testing.

Mechanism of Action

Mechanism of Action: Physiochemical Modulation

Extancin acts as a physiochemical modulator, exerting its effect primarily on the aqueous layer coating the respiratory epithelium. This action is peripheral, occurring within the airways and not involving central receptor or enzyme inhibition. The drug influences the rheology (flow properties) of the mucus by incorporating water molecules into the secreted mucin matrix, likely through osmotic or physical forces. This targeted hydration decreases the overall viscosity and adhesiveness of respiratory tract secretions.

This decrease in viscosity leads to the modulation of the mucociliary clearance system. Optimizing the fluid properties of the secretions permits the microscopic cilia on the airway epithelial cells to transport the thinned mucus more effectively. This mechanistic cascade results in a system-level physiological consequence: an increased clearance rate of secretions from the respiratory passages.

Dosage and Administration Information

How to Use Extancin: Official Administration Guidelines

Extancin (Guaifenesin) is administered orally according to standardized labeling protocols. The method of use is defined by the formulation's release mechanism, frequency, and specific handling requirements.


Official Dosing and Frequency

Feature Official Labeled Instruction
Route of Administration Oral administration only.
Immediate-Release (IR) Dosing Adults (12+ years): 200 mg to 400 mg per dose, taken every 4 hours as needed.
Extended-Release (ER) Dosing Adults (12+ years): 600 mg to 1200 mg per dose, taken every 12 hours.
Maximum Daily Limit The total quantity consumed from all forms must not exceed 2,400 mg in a 24-hour period.

Administration Requirements and Handling

Extancin use is structured around intermittent, as-needed symptom management. Oral doses should be consumed with a full glass of water and may be taken irrespective of meal timing. Liquid formulations require measurement using an accurate, calibrated device. Pediatric doses for the immediate-release forms are scaled down based on age group. Extended-release tablets are generally not intended for use in children under 12 years of age and must not be crushed, broken, or chewed to preserve the controlled-release mechanism. If a dose is missed, the next dose should be taken at the regularly scheduled time without attempting to double the amount.

Recent Clinical Evidence

Extancin: Recent Clinical Evidence


Evidence for Research Examining Acute Chest Congestion

The research base for Extancin primarily focused on short-term investigation, including randomized controlled trials (RCTs) and subsequent systematic reviews. Studies explored changes in subjective symptoms, such as cough frequency and intensity, and examined objective changes in sputum properties in otherwise healthy adults and adolescents with acute upper respiratory tract infections (URTI). Findings across systematic reviews were mixed and inconsistent, leading to an evidence rating of moderate. Results apply only to the specific populations studied, and certainty remains low regarding the consistency of effects.


Evidence for Research Examining Symptoms in Stable Chronic Bronchitis

Research for the extended-release formulation has been directed at conditions like stable chronic bronchitis. The evidence base relies on open-label, single-cohort investigations (RWE studies) and limited historical controlled data. Studies monitored adults aged 40 or older by assessing patient-reported outcomes (PROMs), specifically tracking cough and sputum severity over follow-up periods of up to 12 weeks. This intermediate-term evidence for the extended-release formulation is reflected in its regulatory classification.


Research Gaps and Uncertainty

Studies for acute conditions have follow-up durations that were limited, typically not exceeding one week. Long-term effects are not fully established for Extancin, and controlled trial data for prolonged use is historically lacking. Research provides limited insight into specific subgroups, such as those with significant comorbidities. The evidence quality varies across studies, and findings describing group patterns do not translate to individual predictions.

Key Studies & References

  1. Guaifenesin Extended Release - FDA Labeling and Monograph Information (DailyMed)
  2. A Study to Explore if Long-term Use of Mucinex Can Help With Symptoms in Patients With Stable Chronic Bronchitis (GASP Study - ClinicalTrials.gov)

Frequently Asked Questions (FAQ)

Common questions about Extancin (FAQ)


Q: Is Extancin considered a short-term or long-term medication?

A: Official information generally specifies use for acute conditions should typically not exceed seven days without a medical review. However, the extended-release form has been examined in studies lasting up to twelve weeks for conditions like stable chronic bronchitis, indicating intermediate-term use is sometimes explored.

Q: Does Extancin treat the cause or just the symptoms?

A: Extancin is officially classified as an expectorant, a type of medicine that helps relieve symptoms. Its mechanism of action is described as targeting symptoms by thinning and loosening mucus to aid its clearance. Regulatory information does not describe a mechanism to address the underlying cause of the condition.

Q: How long does Extancin stay in the system after stopping it?

A: Regulatory information indicates that the active ingredient, guaifenesin, is rapidly metabolized and excreted by the body. The plasma half-life—the time it takes for half the drug to be eliminated—is approximately one hour.

Q: What does the official drug information say about using Extancin with alcohol?

A: Official labeling for single-ingredient Extancin (guaifenesin) does not typically list a specific interaction with alcohol. However, it is important to check the label for any warnings, especially if the product is a combination medicine that includes ingredients that can cause drowsiness or interact with alcohol.

Q: Is Extancin safe to use if I have kidney issues?

A: Official documentation advises caution and consultation with a health professional for patients who have severe renal impairment (significant kidney disease). This caution is noted because the drug is primarily eliminated from the body via the kidneys.

Q: Is Extancin safe for people with a history of liver problems?

A: Extancin is formally contraindicated (should not be used) in individuals who have severe hepatic disease (severe liver disease). For all other liver problems or history of issues, a health professional must be consulted due to the rare, but serious, risk of liver injury known as Hepatotoxicity.

Q: What kind of research has been done on the long-term use of Extancin?

A: Official sources state that long-term effects are not fully established, and controlled trial data for prolonged use are historically lacking for the acute condition. Research for the extended-release form has, however, included studies up to 12 weeks when used for stable chronic bronchitis.

Q: What are the most commonly reported reasons for stopping Extancin?

A: The most common reasons for adverse reactions leading to potential cessation are typically related to frequently reported side effects, such as nausea, headache, vomiting, and dizziness. Additionally, official guidelines mandate immediate cessation if signs of a serious reaction, such as a severe skin rash or clinically significant liver enzyme elevation, appear.

Q: Does Extancin interfere with blood pressure medication?

A: Regulatory documents state that single-ingredient Extancin has a profile largely free of documented pharmacokinetic drug-drug interactions. This means the drug's metabolism is unlikely to directly affect the levels of most other prescription medications, including common blood pressure medicines.

Q: What should I do if a side effect of Extancin seems to be getting worse?

A: Official regulatory documents indicate that consultation with a health professional is advised if the cough persists for more than seven days, returns, or is accompanied by a fever, rash, or persistent headache. Treatment discontinuation is also required at the first sign of a serious skin reaction or clinically significant liver enzyme elevation.

Q: Can Extancin be used by teenagers?

A: Official eligibility criteria indicate that the drug is generally deemed eligible for use by Adults and Children 12 years of age and over, a group which includes teenagers.

Q: Are there specific food types to avoid while taking Extancin?

A: Official regulatory information states that the product can be administered without regard to the timing of meals. No specific food types are listed as being restricted or needing to be avoided while taking this medication.

Q: What happens if I forget to take a dose of Extancin?

A: Official administration requirements advise that if a dose is missed, the next dose should be taken at the regularly scheduled time. Doubling the amount to compensate for the missed dose is not recommended.

Q: Is it okay to drive or operate machinery after taking Extancin?

A: Commonly documented adverse reactions include effects such as drowsiness, headache, and general fatigue, which are effects involving the nervous system. Regulatory information concerning medicines with these effects notes that they have the potential to impair the ability to drive or operate machinery.

Q: Is there a risk of dependence or withdrawal with Extancin?

A: Extancin, as a single-ingredient guaifenesin product, is not classified as a controlled substance by regulatory bodies. It is not associated with a risk of dependence or withdrawal.

Q: Does Extancin have a black box warning?

A: Extancin, as a single-ingredient guaifenesin product, does not carry a black box warning from the FDA. These warnings are present only on specific combination products that contain other, higher-risk ingredients, such as certain opioids.

Q: What is the general timeline for a typical Extancin treatment course?

A: For acute, as-needed use, regulatory instructions advise patients to stop using the medication and seek professional advice if the cough persists for more than seven days. This suggests a typical course is generally less than one week.

Q: Can Extancin change your appetite?

A: Official adverse reaction lists commonly document effects on the Gastrointestinal System, such as nausea and vomiting. While a direct change in appetite is not listed, these related gastrointestinal effects could indirectly influence eating habits.

Q: Is Extancin safe for people with heart conditions?

A: Official documentation does not list specific heart conditions as a contraindication or restriction for single-ingredient Extancin. Unlike some other cold and cough ingredients, the product does not typically affect blood pressure or heart rate at therapeutic doses.

Q: What are the signs of a serious allergic reaction to Extancin?

A: Regulatory documents list the risk of serious Hypersensitivity/Anaphylaxis. Signs of a serious allergic reaction often include hives, swelling of the face, lips, tongue, or throat, and difficulty breathing.

Q: Is Extancin a controlled substance?

A: Extancin, as a single-ingredient guaifenesin product, is not classified as a controlled substance under the DEA or other similar governmental bodies.

Q: Do official sources mention any long-term effects of Extancin that are not side effects?

A: Official sources state that long-term effects are not fully established and that long-term controlled trial data are historically lacking. Therefore, long-term effects beyond those noted in the short-to-intermediate term studies are not officially documented.

Q: Can I take other prescription drugs with Extancin?

A: Regulatory documents indicate that single-ingredient Extancin has a profile largely free of documented pharmacokinetic drug-drug interactions. However, co-administration with other cough and cold medicines, especially cough suppressants, is not recommended because it may counteract the intended effects of Extancin.

Q: Does Extancin work immediately or build up over time?

A: The drug's mechanism is a physiochemical modulation of mucus properties, and its use is structured around intermittent, as-needed symptom management. This suggests an acute effect is experienced rather than a gradual 'build up' of the medicine over time.

Q: Does Extancin interact with birth control pills?

A: Regulatory information for single-ingredient Extancin (guaifenesin) does not document any clinically significant interaction that affects the metabolism or effectiveness of oral birth control pills.

Q: Are there any known interactions between Extancin and herbal supplements?

A: Official documentation for Extancin is focused on interactions with prescription and over-the-counter medicines. These regulated documents typically do not contain comprehensive information regarding specific interactions with all herbal supplements.

How should Extancin be stored and disposed of?

How to Store and Dispose of Extancin

Extancin (Guaifenesin Extended-Release) must be stored under specific regulatory conditions to maintain stability and safety. The official requirement is Controlled Room Temperature, which is defined as 20°C to 25°C (68°F to 77°F). The medicine must be protected from moisture and kept from freezing.

Packaging and Safety

  • The product must not be used after the expiration date or if the blister seal is broken.
  • It is mandatory to store Extancin out of the sight and reach of children.

Disposal

Unused or expired product should be discarded according to official government instructions. The recommended procedure is to utilize a drug take-back program. Medicines should not be disposed of by flushing them down a toilet or pouring them down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Extancin found in:

A-Z Index: